Management of Cardiovascular Risk Factors

AstraZeneca1 site in 1 country1,492 target enrollmentFebruary 2009

ConditionsCardiovascular Risk Factors Cardiovascular Diseases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cardiovascular Risk Factors
Sponsor: AstraZeneca
Enrollment: 1492
Locations: 1
Primary Endpoint: The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia.
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia

Registry

clinicaltrials.gov

Start Date

February 2009

End Date

December 2009

Last Updated

15 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Eligibility Criteria

Inclusion Criteria

•Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
•Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
•Patients received during the observation time new cholesterol lowering and hypertension treatment

Exclusion Criteria

•Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment

Outcomes

Primary Outcomes

The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia.

Time Frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit